RecruitingEarly Phase 1NCT05043701
Individualized Systems Medicine Functional Profiling for Recurrent Glioblastoma
Individualized Systems Medicine Strategy for Targeting Cancer Stem Cells in Patients With Recurrent Glioblastoma (ISM-GBM)
Sponsor
Oslo University Hospital
Enrollment
15 participants
Start Date
Mar 1, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
A study to determine the feasibility and safety of individualized cancer stem cell targeted therapy based on high-throughput functional profiling of FDA/EMA-approved drugs in patients with GBM that has recurred or progressed following standards-of-care (RT, TMZ).
Eligibility
Min Age: 18 YearsMax Age: 70 Years
Inclusion Criteria7
- Recurrence of histologically verified glioblastoma
- Adequate biopsy to generate enough live cells to allow functional screening
- Must be ambulatory with an Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Must be 18 to 70 years of age
- Adequate bone marrow, liver and heart function
- Must be competent to give consent
- Signed informed consent and expected cooperation of the patients for the treatment and follow up must be obtained and documented according to International Conference on Harmonization Good Clinical Practice guidelines (ICH GCP), and national/local regulations.
Exclusion Criteria2
- Patients taking part in other clinical trials which could make inclusion or follow-up difficult
- Any reason why, in the opinion of the investigator, the patient should not participate
Interventions
DRUGPersonalized drug combination
A personalized drug combination will be prescribed to each patient based on the functional drug screen
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05043701
Related Trials
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
NCT06325683317 locations
Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
NCT074809411 location
Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
NCT063441301 location
Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells
NCT061864011 location
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
NCT072972121 location